Strong Q1 beat across all metrics with reiterated guidance suggests accelerating momentum. Watch for FDA filing in Q2 2026 for PTSD indication, which could expand TAM. The $8.5 million in financial asset purchases (likely convertible loans) signals active capital deployment but also cash burn, monitor cash position in subsequent quarters.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 13 $16.84entry
- T+1 · 6mo ago 0.00%α −0.78% · $16.84
- T+5 · 6mo ago 0.00%α +1.16% · $16.84
- T+20 · 5mo ago 0.00%α +0.61% · $16.84
- T+60 · 3mo ago −10.15%α −14.59% · $15.13
Price Chart
How similar events traded
Executive Summary
BrainsWay reported Q1 2026 revenue of $15.5 million (up 35% YoY) and net income of $2.3 million (up >100% YoY), with Adjusted EBITDA more than doubling to $2.8 million. The company reiterated full-year 2026 guidance of $66-$68 million in revenue and $12-$14 million in Adjusted EBITDA, supported by record system shipments and expanding payer coverage.
Key Facts
- Q1 2026 revenue of $15.5 million, up 35% from $11.5 million in Q1 2025
- Net income of $2.3 million, up >100% from $1.1 million in Q1 2025
- Adjusted EBITDA of $2.8 million, up 117% from $1.3 million in Q1 2025
- Operating income of $2.0 million, up from $0.6 million in Q1 2025
- Gross margin steady at 75%
- Shipped 117 Deep TMS systems in Q1 2026, up 44% YoY; installed base ~1,820 systems
- Remaining performance obligations of $75 million, up 25% YoY
- Cash and equivalents of $58.6 million as of March 31, 2026
- Reiterated FY2026 guidance: revenue $66-$68 million, operating income 13%-14% of revenue, Adjusted EBITDA $12-$14 million
- Completed $6 million convertible loan to Neurolief and $1 million minority stake in BrainStim Health Inc.
Financial Impact
Revenue growth of 35% YoY to $15.5 million, net income more than doubled to $2.3 million, Adjusted EBITDA up 117% to $2.8 million
Risk Factors
- Cash and equivalents declined from $67.7 million to $58.6 million in Q1 2026, partly due to $8.5 million in financial asset purchases
- Trade receivables increased to $7.5 million from $4.1 million, indicating potential collection risk
- Ongoing patent litigation with Magnus Medical noted in prior 20-F filing
- Reliance on single large customer as noted in prior annual report
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003345 |
| Document: f6k_051226.htm | 0001171843-26-003345 |
| Document: 0001171843-26-003345-index-headers.html | 0001171843-26-003345 |
| Document: 0001171843-26-003345-index.html | 0001171843-26-003345 |
| Document: 0001171843-26-003345.txt | 0001171843-26-003345 |
Track record
5 reports on BRSYF
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +24.28% at T+20 after the Apr 15, 2026 report. 2 of 3 went positive at some point.
Filters
- Jun 9, 202622w ago 6-K Bullish 7/10 Entry $16.84 to $15.13 Now $10.62 −36.94% ▼ −10.15% −14.24% vs SPY
- May 18, 202626w ago 6-K Neutral 4/10 Entry $16.84 to $15.13 Now $10.62 −36.94% ▼ −10.15% −15.01% vs SPY
- May 13, 202626w ago 6-K Bullish 8/10 Viewing Entry $16.84 to $15.13 Now $10.62 −36.94% ▼ −10.15% −14.59% vs SPY
- Apr 20, 202630w ago 20-F Bullish 7/10 Entry $13.55 to $15.13 Now $10.62 −21.62% ▲ +11.66% +4.76% vs SPY
- Apr 15, 202630w ago 6-K Bullish 7/10 Entry $13.55 to $15.13 Now $10.62 −21.62% ▲ +11.66% +3.52% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers